Brexpiprazole (Rexulti) (Brexpiprazole) for Personal Injury

Drug Class: Atypical Antipsychotic / PTSD Adjunctive Therapy (D2/5-HT1A Partial Agonist)

Common Uses

  • Adjunctive treatment for PTSD in adults (FDA-approved 2023)
  • PTSD following car accidents, assaults, or traumatic injury
  • Residual PTSD symptoms inadequately controlled by SSRI monotherapy
  • Adjunctive treatment for major depressive disorder

How It Helps in Personal Injury Cases

Motor vehicle accidents are the leading cause of PTSD in the general US population. Brexpiprazole (Rexulti) received FDA approval specifically for adjunctive PTSD treatment in May 2023 — the first new PTSD drug approval in over 20 years. In personal injury cases, a Rexulti prescription documents a formal PTSD diagnosis of sufficient severity to require pharmacotherapy beyond first-line SSRI treatment. The 2023 FDA PTSD indication is recent enough that many attorneys have not yet encountered it — representing a strong documentation opportunity for psychological injury claims.

Brexpiprazole is a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, and an antagonist at serotonin 5-HT2A receptors. This receptor profile is distinct from SSRIs and explains why adding brexpiprazole provides additional benefit in patients with residual PTSD symptoms on SSRI therapy. It does not directly affect norepinephrine reuptake (unlike SNRIs) but modulates the dopamine and serotonin pathways involved in threat processing, fear extinction, and emotional regulation — processes disrupted in PTSD.

Brexpiprazole (Rexulti) for PTSD After a Personal Injury

Brexpiprazole, sold as Rexulti, received FDA approval in May 2023 as an adjunctive treatment for PTSD in adults — the first new PTSD-specific drug approval in over 20 years.

PTSD After Car Accidents

Motor vehicle accidents are the most common cause of PTSD in the general population. The traumatic experience of a crash, combined with physical pain, disrupted daily function, and ongoing medical treatment, creates the conditions for PTSD to develop and persist. When PTSD does not adequately respond to first-line SSRI therapy alone, psychiatrists add adjunctive medications like brexpiprazole.

Mechanism

Brexpiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2A receptors. This combined receptor activity modulates the brain circuits involved in threat processing, fear extinction, and emotional regulation — processes specifically disrupted in PTSD.

Dosing

Starting at 0.5mg daily, titrated to 1-2mg daily. Maximum dose 3mg daily. Taken once daily, with or without food.

Significance in PI Cases

A Rexulti prescription documents:

  1. A formal PTSD diagnosis — not just anxiety or stress
  2. Treatment failure on SSRI monotherapy — severity sufficient to require adjunctive pharmacotherapy
  3. Specialist-level psychiatric care — prescribers are typically psychiatrists
  4. The most recently FDA-approved PTSD medication — strong evidence of evidence-based treatment

Many personal injury attorneys have not yet encountered the 2023 PTSD indication for Rexulti — representing an opportunity to document psychological injury with the newest available pharmacological evidence.

Accessing Brexpiprazole Through LienScripts

Brexpiprazole (Rexulti) is brand-name only. LienScripts provides pharmacy lien coverage at $0 upfront cost for qualified personal injury patients.

Dosage Forms

  • Tablet 0.5mg (starting dose)
  • Tablet 1mg
  • Tablet 2mg (typical target dose)
  • Tablet 3mg (maximum dose, less common)
  • Taken once daily

Common Side Effects

  • Weight gain
  • Somnolence (drowsiness — less than older antipsychotics)
  • Akathisia (restlessness — uncommon at PTSD doses)
  • Headache
  • Fatigue

Frequently Asked Questions

Can a car accident cause PTSD requiring Rexulti?

Yes. Motor vehicle accidents are the most common cause of PTSD in the general population. PTSD from an accident produces the same neurobiological changes — altered HPA axis, amygdala hyperactivity, fear extinction deficits — as PTSD from any other trauma. When PTSD is inadequately controlled by first-line SSRI therapy, adjunctive brexpiprazole (Rexulti) is appropriate.

Is Rexulti a controlled substance?

No. Brexpiprazole is not a controlled substance. It is an atypical antipsychotic with no abuse or dependence potential.

Why is the 2023 PTSD approval significant for PI cases?

The 2023 FDA approval of brexpiprazole for PTSD was the first new PTSD-specific drug approval in over 20 years. It documents that the psychiatric community specifically validated this mechanism for PTSD treatment. A Rexulti prescription reflects a formal PTSD diagnosis treated with the most recently FDA-approved PTSD pharmacotherapy — very difficult to minimize in litigation.

Is there a generic version of Rexulti?

No. Brexpiprazole is available only as Rexulti. There is no generic alternative.